Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer - Scorecard - MDSpire

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • By

  • Meghna S. Trivedi

  • Joseph M. Unger

  • N. Lynn Henry

  • Amy K. Darke

  • Daniel L. Hertz

  • Thomas H. Brannagan

  • Stephanie J. Reyes

  • Bryan P. Schneider

  • William J. Irvin

  • Amanda R. Hathaway

  • Amy C. Vander Woude

  • Vinay K. Gudena

  • Paula Cabrera-Galeana

  • Mary Orsted

  • Michael LeBlanc

  • Michael J. Fisch

  • Dawn L. Hershman

  • April 10, 2026

  • 0 min

Share

Clinical Scorecard: Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

At a Glance

CategoryDetail
ConditionTaxane-Induced Peripheral Neuropathy (TIPN)
Key MechanismsCumulative taxane dose, frequency of dosing, type of taxane, and patient-related risk factors.
Target PopulationPatients aged 18 years or older with stage I to III non-small cell lung cancer or breast, ovarian, fallopian tube, or primary peritoneal cancer receiving taxane-based treatment.
Care SettingOncology clinics conducting taxane-based chemotherapy.

Key Highlights

  • TIPN occurs in up to 70% of patients receiving taxanes.
  • Management primarily involves taxane dose modification.
  • Numerous patient-related and treatment-related risk factors identified.
  • Prospective observational study with 3 years of follow-up.
  • CIPN-20 scale used for assessing neuropathy symptoms.

Guideline-Based Recommendations

Diagnosis

  • Use the CIPN-20 scale to assess sensory neuropathy.

Management

  • Consider taxane dose modification as the mainstay of management.

Monitoring & Follow-up

  • Conduct serial assessments of TIPN at baseline and at 4, 8, 12, and 24 weeks.

Risks

  • Dose reductions may adversely affect long-term outcomes such as overall survival.

Patient & Prescribing Data

Patients with early-stage cancer receiving taxane-based chemotherapy.

Risk factors include demographic, lifestyle, comorbid conditions, and genetic factors.

Clinical Best Practices

  • Utilize a risk prediction model to identify high-risk patients.
  • Implement standardized trial data collection and quality checks.
  • Follow ethical guidelines and obtain informed consent from participants.

References

Original Source(s)

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • by Meghna S. Trivedi, Joseph M. Unger, N. Lynn Henry, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan, Stephanie J. Reyes, Bryan P. Schneider, William J. Irvin, Amanda R. Hathaway, Amy C. Vander Woude, Vinay K. Gudena, Paula Cabrera-Galeana, Mary Orsted, Michael LeBlanc, Michael J. Fisch, Dawn L. Hershman

  • April 10, 2026

Related Content

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

HiGATE: hierarchical graph attention for multi-scale tissue encoder in computational pathology